Renal Insufficiency, Chronic Clinical Trial
Official title:
Effects of Low Level Laser Therapy on Functional Capacity and DNA Damage of Patients With Chronic Kidney Failure on Hemodialysis: Randomized Clinical Trial
This study aims to verify the effects of low level laser therapy (LLLT) on functional
capacity, DNA damage, lower limbs muscle strength, quadriceps muscle architecture, muscle
pain and perception of lower limb fatigue, inflammatory profile, oxidative stress and quality
of life of patients with chronic kidney failure on hemodialysis. Patients will be randomized
into two groups: the control group and the LLLT group. The control group will only be
evaluated and reassessed. The LLLT group in addition to the evaluations will receive LLLT
three times a week for eight weeks during HD. The evaluations will be performed
pre-intervention, after 4 and 8 weeks of therapy. However, the muscle architecture evaluation
will be performed only at pre intervention and after 8 weeks.
The evaluations carried out are: six-minute walk test for functional capacity; alkaline comet
assay for DNA damage; sit-and-lift test, and load cell dynamometry for evaluation of lower
limbs muscle strength; quadriceps ultrasonography for muscle architecture and echogenicity;
visual analogue scale for pain; subjective perception of effort by Borg scale for fatigue;
measurement of interleukins 6 and 10, tumor necrosis factor, reative C protein and muscle
damage markers (lactate, creatine kinase) for the inflammatory profile; protein
carbonylation, superoxide dismutase, catalase, total sulfuric acid and dichlorofluorescein
diacetate for oxidative stress and application of the Kidney Disease and
Quality-of-Life-Short-Form and EQ-5D questionnaires for quality of life.
Chronic kidney disease (CKD) consists of kidney damage and progressive and irreversible loss
of kidney function and in its later stage (terminal phase) is called chronic kidney failure
(CKF). Although hemodialysis (HD) substitutes some of the lost renal functions, patients
suffer from some changes that characterize uremic syndrome, such as peripheral motor
neuropathy, osteomalacia, cardiac and musculoskeletal myopathies, anemia, among other
alterations.
This study aims to verify the effects of low level laser therapy (LLLT) on functional
capacity, DNA damage, lower limbs muscle strength, quadriceps muscle architecture, muscle
pain and perception of lower limb fatigue, inflammatory profile, oxidative stress and quality
of life of patients with chronic kidney failure on hemodialysis. Patients will be randomized
into two groups: the control group and the LLLT group. The control group will only be
evaluated and reassessed. The LLLT group in addition to the evaluations will receive LLLT
three times a week for eight weeks during HD. The evaluations will be performed
pre-intervention, after 4 and 8 weeks of therapy. However, the muscle architecture evaluation
will be performed only at pre intervention and after 8 weeks.
The evaluations carried out are: a six-minute walk test for functional capacity; alkaline
comet assay for DNA damage; sit-and-lift test, and load cell dynamometry for evaluation of
lower limbs muscle strength; quadriceps ultrasonography for muscle architecture and
echogenicity; visual analogue scale for pain; subjective perception of effort by Borg scale
for fatigue; measurement of interleukins 6 and 10, tumor necrosis factor, reative C protein
and muscle damage markers (lactate, creatine kinase) for the inflammatory profile; protein
carbonylation, superoxide dismutase, catalase, total sulfuric acid and dichlorofluorescein
diacetate for oxidative stress and application of the Kidney Disease and
Quality-of-Life-Short-Form and EQ-5D questionnaires for quality of life.
The expected results at the end of the protocol are: greater distance covered in the walking
test; reduction of DNA damage, increase in lower limbs strength; maintenance of muscle mass;
reduction of pain and fatigue levels as well as the inflammatory profile and levels of
oxidative stress, as well as improvement in the quality of life for the group LLLT.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT05056727 -
A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia
|
Phase 3 | |
Withdrawn |
NCT01655186 -
A Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Effects of Bardoxolone Methyl on Body Composition in Patients With Stage 4 Chronic Kidney Disease and Type 2 Diabetes Mellitus
|
Phase 2 | |
Completed |
NCT03481686 -
Therapeutic Education of Chronic Renal or Renal Transplant Patient in the Management of EPO Injections
|
N/A | |
Active, not recruiting |
NCT03672110 -
Slow and Low Start of a Tacrolimus Once Daily Immunosuppressive Regimen
|
Phase 3 | |
Enrolling by invitation |
NCT02237534 -
Lanthanum Versus Calcium Carbonate for Vascular Abnormalities in Patients With CKD and Hyperphosphatemia
|
Phase 4 | |
Completed |
NCT02126293 -
Correction of Zinc Deficiency in Children With Chronic Kidney Disease and Kidney Transplant
|
Phase 3 | |
Terminated |
NCT01533545 -
Effect of Epinephrine on Systemic Absorption of Mepivacaine in Uremic Patients
|
N/A | |
Completed |
NCT03280615 -
Omega 3 Fatty Acids in Patients With Chronic Renal Disease
|
Phase 3 | |
Completed |
NCT04498156 -
Survey of Patient and Physician Awareness and Values to the Diagnosis and Treatment of Reduced Kidney Function (Chronic Kidney Disease) in Patients With High Blood Sugar Level (Type 2 Diabetes) (AWARE-CKD in T2D)
|
||
Recruiting |
NCT04020328 -
Leflunomide Plus Low Dose Corticosteroid in Immunoglobulin A (IgA) Nephropathy With Renal Insufficiency
|
Phase 4 | |
Recruiting |
NCT06366529 -
Explore New Magnetic Resonance Technology in Assessment of Renal Dysfunction
|
||
Active, not recruiting |
NCT04876963 -
HOLT-ED: Holter-monitoring in End-stage Renal Disease
|
||
Completed |
NCT03836508 -
Effect of Dialysis Membranes on Inflammatory and Immune Processes in Hemodialysis
|
N/A | |
Completed |
NCT03577249 -
Biological Effects of Citrate-buffered Solutions on Dialysis Efficiency and Systemic Inflammation
|
Phase 2/Phase 3 | |
Completed |
NCT01975818 -
Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934
|
Phase 2 | |
Active, not recruiting |
NCT05766644 -
App-based Education Program for CKD
|
N/A | |
Active, not recruiting |
NCT02791880 -
Acute Kidney Injury Genomics and Biomarkers in TAVR Study
|
||
Recruiting |
NCT02947750 -
Neurovascular Transduction During Exercise in Chronic Kidney Disease
|
Phase 2 | |
Terminated |
NCT02286258 -
Validation of New Markers of Glomerular Filtration Rate: Dota Gadolinium and Calcium EDTA (MultiGFR)
|
Phase 1/Phase 2 | |
Completed |
NCT01711853 -
Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate in Patients With Stable Severe Renal Disease.
|
Phase 1 |